FrancophonIA/ELRC3.0 huggingface dataset:
English: • KRYSTEXXA vial should be visually inspected for particles and discolouration prior to dilution and administration.
Estonian: • Enne lahjendamist ja manustamist tuleb KRYSTEXXA viaali visuaalselt kontrollida nähtavate osakeste ja värvimuutuste suhtes.
English: Patients should be pre-treated with antihistamines, corticosteroids, and paracetamol, and closely monitored for the onset of adverse reactions suggesting severe hypersensitivity reactions including anaphylaxis for at least 1 hour after the end of the infusion (see section 4.8).
Estonian: Neid tuleb rasketele ülitundlikkusreaktsioonidele, sealhulgas anafülaksiale viitavate kõrvaltoimete suhtes hoolikalt jälgida vähemalt ühe tunni vältel pärast infusiooni lõppu (vt lõik 4.8).
English: Water for injections
Estonian: Juhised infusioonilahuse valmistamiseks
English: Anti-PEG antibodies also developed in 41% of patients treated with KRYSTEXXA 8 mg every 2 weeks.
Estonian: 41%-l KRYSTEXXAt annuses 8 mg iga 2 nädalat tagant saanud patsientidest tekkisid samuti PEGvastased antikehad.
English: KRYSTEXXA does not need to be discontinued because of a gout flare.
Estonian: Podagra ägenemise tõttu ei ole vaja ravi KRYSTEXXAga katkestada.
English: Disodium hydrogen phosphate dihydrate Sodium dihydrogen phosphate dihydrate Sodium chloride
Estonian: Dinaatriumvesinikfosfaatdihüdraat Naatriumdivesinikfosfaatdihüdraat Naatriumkloriid
English: Among the other secondary endpoints, reduction from baseline in the number of tender and swollen joints were observed in patients treated with KRYSTEXXA every 2 weeks while there was little change in patients on placebo.
Estonian: Ülejäänud teiseste tulemusnäitajate osas täheldati KRYSTEXXA annusega 8 mg iga 2 nädala tagant ravitud patsientidel lähtetasemega võrreldes valulike ja tursunud liigeste arvu vähenemist, samas kui platseeboga ravitud patsientidel see oluliselt ei muutunud.
English: People with gout have too much uric acid in their body.
Estonian: Podagrahaigete inimeste organismis on liiga palju kusihapet.
English: Very common: Gout flare
Estonian: Väga sage: iiveldus.
English: The most common signs and symptoms of local infusion reactions are: erythema, pruritus, and rash.
Estonian: Lokaalse infusiooniga seotud reaktsiooni kõige sagedamad nähud ja sümptomid on erüteem, nahakihelus ja nahalööve.
English: How to store KRYSTEXXA
Estonian: Kuidas KRYSTEXXAt säilitada
English: No formal studies were conducted to examine the effects of hepatic impairment.
Estonian: Spetsiaalseid uuringuid maksakahjustuse mõju hindamiseks ei ole läbi viidud.
English: No dose adjustment is needed for patients 65 years of age and older.
Estonian: 65-aastastel ja vanematel patsientidel ei ole vaja KRYSTEXXA annust kohandada.
English: Adverse Reaction
Estonian: Seedetrakti häired
English: How KRYSTEXXA is administered
Estonian: Kuidas KRYSTEXXAt manustatakse
English: The most common signs and symptoms of local infusion reactions were: redness at the injection site, itching, and rash.
Estonian: Paikse infusioonireaktsiooni kõige sagedamad nähud ja sümptomid olid punetus infusioonikohas, nahasügelus ja lööve.
English: Lot
Estonian: VIAAL
English: Blood and lymphatic disorders
Estonian: Vere ja lümfisüsteemi häired Üldised häired ja manustamiskoha reaktsioonid
English: Breast-feeding
Estonian: Peglotikaas
English: Uncommon: Cellulitis
Estonian: Sage: hüperglükeemia.
English: Contents of the pack and other information
Estonian: Kuidas KRYSTEXXAt säilitada Pakendi sisu ja muu teave
English: The Pain scores using a visual analogue scale were 44.2 at baseline vs. 28.4 at Week 25 in patients treated with pegloticase 8 mg every 2 weeks compared to 53.9 vs. 57.2 in the placebo group (p≤0.001).
Estonian: nädalal 28,4 võrrelduna vastavalt 53,9 vs. 57,2 platseeborühmas (p ≤ 0,001).
English: Very common: Infusion related reaction Common: Anaphylaxis, influenza like illness
Estonian: Väga sage: infusiooniga seotud reaktsioonid.
English: Grounds recommending the variation to the terms of the Marketing Authorisation
Estonian: Müügiloa tingimuste muutmise soovituse alused
English: Musculoskeletal and connective tissue disorders
Estonian: naatriumkloriid ja süstevesi.
English: EXP
Estonian: Platseebo
English: Metabolism and nutrition disorders Common: Hyperglycaemia Cardiac disorders
Estonian: Aeg-ajalt: hüperkaleemia.
English: vials (glass)
Estonian: (klaas)
English: Intraperitoneal use
Estonian: Sublutaanne või intravenoosne
English: EU/1/97/030/053 Insuman Infusat 100 IU/ml
Estonian: EU/1/97/030/053 Insuman Infusat
English: EU/1/97/030/203 Insuman Implantable
Estonian: EU/1/97/030/054 Insuman Infusat
English: 1 pre-filled syringe
Estonian: 1 eeltäidetud süstal
English: Content
Estonian: Nimi
English: Recombinant Hepatitis B surface antigen (S protein), adsorbed Inactivated type 1 Poliovirus Inactivated type 2 Poliovirus Inactivated type 3 Poliovirus
Estonian: 1 eeltäidetud süstal + 1 eraldi nõel difteeriatoksoidi teetanusetoksoidi läkaköha antigeenseid komponente: läkaköhatoksoidi filamentoosset hemaglutiniini pertaktiini hepatiit B viiruse rekombinantset pinnaantigeeni (HBs-antigeeni)
English: Invented name Strength Pharmaceutical
Estonian: Tugevus Ravimvorm Manustamistee Pakendi iseloomustus Pakendi sisu
English: The European Commission granted a marketing authorisation valid throughout the EU for Copalia on 16 January 2007.
Estonian: Euroopa Komisjon andis Copalia müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 16. jaanuaril 2007.
English: The full EPAR for Copalia can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Copalia kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Copalia
Estonian: Muu teave Copalia kohta
English: Copalia is taken by mouth as one tablet once a day with some water.
Estonian: Copaliat võetakse suu kaudu üks tablett üks kord ööpäevas koos vähese veega.
English: Copalia amlodipine / valsartan
Estonian: Copalia amlodipiin/valsartaan
English: This is a summary of the European public assessment report (EPAR) for Copalia.
Estonian: See on ravimi Copalia Euroopa avaliku hindamisaruande kokkuvõte.
English: The CHMP decided that Copalia's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Copalia kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: For more information about treatment with Copalia, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Copaliaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Copalia.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The most common side effects with Copalia (seen in between 1 and 10 patients in 100) are headache, nasopharyngitis (inflammation of the nose and throat), influenza (flu), hypokalaemia (low blood potassium levels), various types of oedema (swelling), fatigue (tiredness), flushing (reddening), asthenia (weakness) and hot flushes.
Estonian: Copalia kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on peavalu, nasofarüngiit (nina-neelupõletik), gripp, hüpokaleemia (vere kaaliumivaegus), mitmesugused tursed, väsimus, nahapunetus, asteenia (nõrkus) ja kuumahood.
English: What is Copalia?
Estonian: Mis on Copalia?
English: What is the risk associated with Copalia?
Estonian: Mis riskid Copaliaga kaasnevad?
English: For the full list of all side effects reported with Copalia, see the package leaflet.
Estonian: Copalia kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The company also presented evidence that the levels of amlodipine and valsartan in the blood were the same in people taking Copalia and people taking the separate medicines.
Estonian: Ettevõte esitas ka andmeid, et amlodipiini ja valsartaani sisaldus veres oli Copaliat kasutavatel ning amlodipiini ja valsartaani eraldi kasutavatel patsientidel ühesugune.
English: Copalia is a medicine that contains two active substances, amlodipine and valsartan.
Estonian: Copalia on ravim, mis sisaldab kahte toimeainet, amlodipiini ja valsartaani.
English: Why has Copalia been approved?
Estonian: Miks Copalia heaks kiideti?
English: Copalia is used in patients who have essential hypertension (high blood pressure) that is not adequately controlled on either amlodipine or valsartan taken alone.
Estonian: Copaliat kasutatakse essentsiaalse hüpertensiooniga (kõrgvererõhutõvega) patsientidel, kelle vererõhku ei saa ainult amlodipiini või valsartaaniga piisavalt reguleerida.
English: Copalia contains two active substances, amlodipine and valsartan.
Estonian: Copalia sisaldab kahte toimeainet, amlodipiini ja valsartaani.
English: Copalia must not be used in patients who are hypersensitive (allergic) to amlodipine or other medicines in the ‘dihydropyridine derivatives' class, to valsartan, or to any of the other ingredients.
Estonian: Copaliat ei tohi kasutada patsiendid, kes on amlodipiini või teiste dihüdropüridiini derivaatide klassi kuuluvate ravimite, valsartaani või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: How does Copalia work?
Estonian: Kuidas Copalia toimib?
English: Copalia must not be used in patients who have severe liver or bile problems, patients with certain heart problems and patients with severe hypotension (low blood pressure).
Estonian: või sapiprobleemid, teatud südameprobleemidega patsiendid ega raske hüpotensiooniga (madala vererõhuga) patsiendid.
English: What benefit has Copalia shown during the studies?
Estonian: Milles seisneb uuringute põhjal Copalia kasulikkus?
English: How has Copalia been studied?
Estonian: Kuidas Copaliat uuriti?
English: How is Copalia used?
Estonian: Kuidas Copaliat kasutatakse?
English: What is Copalia used for?
Estonian: Milleks Copaliat kasutatakse?
English: The dose of Copalia to be used depends on the doses of amlodipine or valsartan that the patient was taking before.
Estonian: Copalia annus sõltub patsiendi varasemast amlodipiini või valsartaani annusest.
English: Copalia must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension) in patients with type 2 diabetes or in patients with moderate or severe kidney impairment.
Estonian: II tüüpi diabeediga või mõõduka või raske neerupuudulikkusega patsiendid ei tohi kasutada Copaliat koos aliskireeni sisaldavate ravimitega (essentsiaalse hüpertensiooni ravimid).
English: The medicine can only be obtained with a prescription.
Estonian: Copalia on retseptiravim.
English: Annex I List of the names, pharmaceutical form(s), strength(s) of the medicinal product(s), route(s) of administration, marketing authorisation holder(s) in the member states
Estonian: I lisa Ravimi(te) nimetuste, ravimvormi(de), tugevus(t)e, manustamisviisi(de), müügiloa hoidja(te) loetelu liikmesriikides
English: Sweden Mundipharma AB Mölndalsvägen 30B Göteborg
Estonian: Mundipharma AB Mölndalsvägen 30B Göteborg
English: Mundipharma Pharmaceuticals, S.L.
Estonian: Hispaania Mundipharma Pharmaceuticals, S.L.
English: Mundipharma SAS 100, avenue de Suffren Paris
Estonian: Prantsusmaa Mundipharma SAS 100, avenue de Suffren Paris
English: Mundipharma SAS 100, avenue de Suffren, Paris
Estonian: Prantsusmaa Mundipharma SAS 100, avenue de Suffren, Paris
English: Germany Mundipharma GmbH Mundipharma Str. 2, Limburg
Estonian: Saksamaa Mundipharma GmbH Mundipharma Str. 2, Limburg
English: Germany Mundipharma GmbH Mundipharma Str. 2
Estonian: Saksamaa Mundipharma GmbH Mundipharma Str. 2
English: Oxycodone hydrochloride/ Naloxone hydrochloride dihydrate (Naloxone hydrochloride)
Estonian: Oksükodoonvesinikkl oriid / naloksoonvesinikklor iiddihüdraat (naloksoonvesinikklo riid)
English: Belgium Mundipharma Comm. VA Blarenberglaan 3C,
Estonian: VA Blarenberglaan 3C,
English: Luxembourg Mundipharma Comm. VA Blarenberglaan 3C
Estonian: VA Blarenberglaan 3C
English: Oxycodone hydrochloride/ Naloxone hydrochloride
Estonian: Oksükodoonvesinikkl oriid / naloksoonvesinikklor iid
English: Further information on Rizmoic can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/rizmoic
Estonian: Lisateave Rizmoici kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/rizmoic.
English: What measures are being taken to ensure the safe and effective use of Rizmoic?
Estonian: Mis meetmed võetakse, et tagada Rizmoici ohutu ja efektiivne kasutamine?
English: The European Medicines Agency therefore decided that Rizmoic's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Seetõttu otsustas Euroopa Ravimiamet, et Rizmoici kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: The recommended dose is one tablet once daily, which the patient can take with or without a laxative.
Estonian: Soovitatav annus on üks tablett üks kord ööpäevas, mida patsient võib võtta koos lahtistiga või ilma.
English: Rizmoic is available as 200 microgram tablets.
Estonian: Rizmoici turustatakse 200 µg tablettidena.
English: The patient must stop taking Rizmoic when they are no longer taking an opioid.
Estonian: Patsient peab lõpetama Rizmoici võtmise, kui talle ei manustata enam opioide.
English: As for all medicines, data on the use of Rizmoic are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Rizmoici kasutamise kohta pidevat järelevalvet.
English: What is Rizmoic and what is it used for?
Estonian: Mis on Rizmoic ja milleks seda kasutatakse?
English: Other information about Rizmoic
Estonian: Muu teave Rizmoici kohta
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rizmoic have been included in the summary of product characteristics and the package leaflet.
Estonian: Rizmoici ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: For more information about using Rizmoic, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Rizmoici kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Side effects reported with Rizmoic are carefully evaluated and any necessary action taken to protect patients.
Estonian: Rizmoici kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: The studies compared Rizmoic with placebo (a dummy treatment) to see if treatment would consistently increase the number of patients who can pass stools and allow them to do so at least 3 times a week during treatment.
Estonian: Uuringutes võrreldi Rizmoici platseeboga (näiv ravim), et veenduda, kas raviga suureneb järjepidevalt nende patsientide arv, kes roojavad vähemalt kolm korda nädalas ravi ajal.
English: In two other studies, involving 307 patients taking opioids for cancer pain, 74% of patients taking Rizmoic for two weeks achieved the desired outcome compared with 36% of patients taking placebo.
Estonian: Veel kahes uuringus, milles osales 307 patsienti, kes võtsid opioide vähi põhjustatud valu raviks, saavutas soovitud tulemuse 74% patsientidest, kes võtsid Rizmoici 2 nädala jooksul, ja 36% platseeborühma patsientidest.
English: Furthermore, the side effects of Rizmoic, which mainly affected the gut, were mostly mild or moderate.
Estonian: Pealegi olid Rizmoici peamiselt soolega seotud kõrvalnähud kerged või mõõdukad.
English: In two of the studies, involving 1095 patients taking opioids for chronic (long-term) pain caused by a condition other than cancer, 50% of patients taking Rizmoic for 12 weeks achieved the desired outcome, compared with 34% of patients taking placebo.
Estonian: Kahes uuringus, milles osales 1095 patsienti, kes võtsid opioide muu haiguse kui vähi põhjustatud kroonilise (pikaajalise) valu raviks, saavutas soovitud tulemuse 50% patsientidest, kes võtsid Rizmoici 12 nädala jooksul, ja 34% platseeborühma patsientidest.
English: Constipation is the most common side effect of opioid pain medicines and many standard laxatives are not effective in treating the condition.
Estonian: Kõhukinnisus on opioidvaluvaigistite kõige sagedam kõrvalnäht ja paljude tavapäraste lahtistitega ei saa seda efektiivselt ravida.
English: Because molecules of naldemedine were designed not be able to enter into the brain, the medicine does not block opioids from working on pain receptors in the brain and therefore does not interfere with pain relief.
Estonian: Kuna naldemediinimolekulid ei pääse ajju, ei blokeeri ravim opioidide toimet ajus asuvatele valuretseptoritele ega mõjuta seega nende valuvaigistavat toimet.
English: What are the risks associated with Rizmoic?
Estonian: Mis riskid Rizmoiciga kaasnevad?
English: The majority of side effects in patients with or without cancer were mild to moderate.
Estonian: Enamik kõrvalnähte nii vähiga kui ka vähita patsientidel olid kerged kuni mõõdukad.
English: The most common side effects with Rizmoic in patients without cancer (which may affect up to 1 in 10 people) are abdominal pain (belly ache), diarrhoea, nausea and vomiting.
Estonian: Rizmoici kõige sagedamad kõrvalnähud muudel kui vähipatsientidel (võivad esineda kuni 1 inimesel 10st) on kõhuvalu, kõhulahtisus, iiveldus ja oksendamine.
English: Rizmoic must not be used in patients with a blocked or perforated bowel or patients at high risk of bowel blockage.
Estonian: Rizmoici ei tohi kasutada patsiendid, kellel on soolesulgus või soolemulgustus või kellel on suur soolesulguse risk.
English: How is Rizmoic used?
Estonian: Kuidas Rizmoici kasutatakse?
English: Rizmoic has been shown to improve bowel movement in patients taking opioids pain medicines for long-term pain (including cancer pain).
Estonian: Rizmoic parandas tõendatult sooletühjendust patsientidel, kes kasutasid opioidvaluvaigisteid pikaajalise valu (sh vähivalu) vastu.
English: It contains the active substance naldemedine.
Estonian: Ravim sisaldab toimeainena naldemediini.
English: Rizmoic is a medicine for treating constipation caused by opioid pain relief medicines in patients who have previously been treated with a laxative (a medicine that triggers bowel movements).
Estonian: Rizmoiciga ravitakse opioidvaluvaigistitest tingitud kõhukinnisust patsientidel, keda on varem ravitud lahtistiga (sooletühjendust soodustav ravim).
English: How does Rizmoic work?
Estonian: Kuidas Rizmoic toimib?
English: In patients with cancer, the most common side effects were diarrhoea (seen in more than 1 in 10 people) and abdominal pain (seen in up to 1 in 10 people).
Estonian: Rizmoici kõige sagedamad kõrvalnähud vähipatsientidel olid kõhulahtisus (esines enam kui 1 inimesel 10st) ja kõhuvalu (esines kuni 1 inimesel 10st).
English: What benefits of Rizmoic have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Rizmoici kasulikkus?
English: Studies have shown that Rizmoic is effective at improving bowel movement in patients who are currently taking laxatives or had taken laxatives in the past.
Estonian: Uuringud on tõendanud Rizmoici efektiivsust sooletühjenduse parandamisel patsientidel, kes võtavad lahtisteid või on neid varem võtnud.
English: An overview of Rizmoic and why it is authorised in the EU
Estonian: Ülevaade ravimist Rizmoic ja ELis müügiloa väljastamise põhjendus
English: The active substance in Rizmoic, naldemedine, works by attaching to and blocking receptors in the gut (mu-, delta- and kappa-opioid receptors), through which opioid medicines cause constipation.
Estonian: Rizmoici toimeaine naldemediin seondub sooles μ-, δ- ja κ-opioidretseptoritega, mille kaudu opioidravimid põhjustavad kõhukinnisust, ning blokeerib need retseptorid.
English: Rizmoic can only be obtained with a prescription.
Estonian: Rizmoic on retseptiravim.
English: Why is Rizmoic authorised in the EU?
Estonian: ELis Rizmoicile väljastatud müügiloa põhjendus
English: MA (EU) number
Estonian: Müügiloa nr Euroopa Liidus (Väljamõel dud) nimetus
English: 3 vials
Estonian: 100 mg/4 ml 3 viaali
English: Tmax is between 3 and 8 hours.
Estonian: Tmax on 3...8 tundi.
English: Tell your doctor or pharmacist if you are taking/using, have recently taken/used or might take/use any other medicines.
Estonian: Teatage oma arstile või apteekrile, kui te võtate/kasutate, olete hiljuti võtnud/kasutanud või kavatsete võtta/kasutada mis tahes muid ravimeid.
English: Some factors that may raise urine pH (see section 5.2 “Elimination”) may necessitate careful monitoring of the patient.
Estonian: Mõnede tegurite tõttu, mis võivad tõsta uriini pH taset (vt lõik 5.2 „Eritumine“), võib olla vajalik patsiendi hoolikas jälgimine.
English: ● if you have a history of epileptic seizures.
Estonian: • Kui teil on kunagi esinenud epilepsiahoogusid.
English: Continue to take Memantine ratiopharm as long as it is of benefit to you.
Estonian: Jätkake Memantine ratiopharmi võtmist senikaua, kui see teile kasulikult mõjub.
English: B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Estonian: B. HANKE- JA KASUTUSTINGIMUSED VÕI PIIRANGUD Piiratud tingimustel väljastatav retseptiravim (vt I lisa: Ravimi omaduste kokkuvõte, lõik 4.2).
English: Talc (E 553b)
Estonian: Talk (E 553b)
English: Slabinská 30, 03680 Martin Slovakia
Estonian: Slabinská 30, 03680 Martin Slovakkia
English: ● dantrolene, baclofen
Estonian: • dantroleen, baklofeen;
English: If tolerated well after at least 7 days of treatment, the dose could be increased up to 20 mg/day according to standard titration scheme.
Estonian: Kui taluvus on hea pärast vähemalt 7-päevast ravi, siis võib annust suurendada kuni 20 mg/ööpäevas vastavalt standardsele tiitrimisskeemile.
English: SL-03680 Martin Slovakia
Estonian: SL-03680 Martin Slovakkia
English: Children and adolescents Memantine ratiopharm is not recommended for children and adolescents under the age of 18 years.
Estonian: Lapsed ja noorukid Memantine ratiopharmi ei soovitata kasutada lastel ja alla 18-aastastel noorukitel.
English: Headache Fatigue 1 Hallucinations have mainly been observed in patients with severe Alzheimer's disease.
Estonian: Peavalu Väsimus 1 Hallutsinatsioone on peamiselt täheldatud raske Alzheimer´i tõvega patsientidel.
English: These compounds act at the same receptor system as memantine, and therefore adverse reactions (mainly central nervous system (CNS)-related) may be more frequent or more pronounced (see also section 4.5).
Estonian: Need ained toimivad samadele retseptoritele nagu memantiin, mistõttu kõrvaltoimeid (peamiselt kesknärvisüsteemiga (KNS) seotud) võib esineda sagedamini või enam väljendunult (vt ka lõik 4.5).
English: Constipation Vomiting Pancreatitis2
Estonian: Kõhukinnisus Oksendamine Pankreatiit2
English: In particular, Memantine ratiopharm may change the effects of the following medicines and their dose may need to be adjusted by your doctor:
Estonian: Memantine ratiopharm võib eriti muuta järgmiste ravimite toimeid ja nende ravimite annused võivad vajada kohandamist teie arsti poolt:
English: ● dopaminergic agonists (substances such as L-dopa, bromocriptine)
Estonian: • dopaminergilised agonistid (näiteks L-dopa, bromokriptiin);
English: It is not known whether memantine is excreted in human breast milk but, taking into consideration the lipophilicity of the substance, this probably occurs.
Estonian: Ei ole teada, kas memantiin eritub rinnapiima, kuid võttes arvesse ravimi lipofiilsust, on see tõenäoline.